Vivani Medical Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$26.3MTTM through 30 Jun 2026
Free Cash Flow -$26.5MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-141.9%ROE
-64.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio3.18x
Net Debt-$19.7Mnet cash position
Cash & Equivalents$19.9M
Quality Metrics
Altman Z-Score-4.14
Piotroski F-Score2 / 9
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPS-$0.36TTMFY2025: $-0.43
Dividend
No dividend
Capital Allocation
R&D Spend$18.1M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biopharm Division | $0 | View detailsSLIM-1 Phase 1 clinical trial of NPM-139 is on track to initiate in mid-2026 with top-line results anticipated by the end of 2026. | |
| Neurostimulation Division (Cortigent) | $0 | View detailsVivani continues to explore strategic options to unlock value, including a potential spin-off or IPO of Cortigent. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.